EQL Pharma AB (publ) (STO:EQL)

Market Cap	2.14B
Revenue (ttm)	338.39M
Net Income (ttm)	34.73M
Shares Out	29.06M
EPS (ttm)	1.19
PE Ratio	61.83
Forward PE	32.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,997
Average Volume	25,303
Open	74.80
Previous Close	74.20
Day's Range	74.20 - 76.20
52-Week Range	32.10 - 77.00
Beta	0.59
RSI	41.90
Earnings Date	May 8, 2025

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In 2023, EQL Pharma AB's revenue was 264.17 million, an increase of 1.64% compared to the previous year's 259.91 million. Earnings were 22.71 million, a decrease of -26.57%.